HUP0302982A2 - Kristályos gyógyszer - Google Patents

Kristályos gyógyszer

Info

Publication number
HUP0302982A2
HUP0302982A2 HU0302982A HUP0302982A HUP0302982A2 HU P0302982 A2 HUP0302982 A2 HU P0302982A2 HU 0302982 A HU0302982 A HU 0302982A HU P0302982 A HUP0302982 A HU P0302982A HU P0302982 A2 HUP0302982 A2 HU P0302982A2
Authority
HU
Hungary
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
pyridylsulfonyl
ethylpiperazine
Prior art date
Application number
HU0302982A
Other languages
English (en)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0302982A2 publication Critical patent/HUP0302982A2/hu
Publication of HUP0302982A3 publication Critical patent/HUP0302982A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány kristályos gyógyszerre vonatkozik, mégpedig az (I) képletű{6-etoxi-5-[3-etil-6,7-dihidro-2-(2-metoxi-etil)-7-oxo-2H-pirazolo[4,3-d]pirimidin-5-il]-3-piridil-szulfonil}-4-etil-piperazinpolimorfra. Ó
HU0302982A 2000-07-28 2001-07-18 Crystalline therapeutic agent HUP0302982A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (2)

Publication Number Publication Date
HUP0302982A2 true HUP0302982A2 (hu) 2003-12-29
HUP0302982A3 HUP0302982A3 (en) 2005-01-28

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302982A HUP0302982A3 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Country Status (46)

Country Link
EP (1) EP1305314B1 (hu)
JP (1) JP2004505087A (hu)
KR (1) KR100457937B1 (hu)
CN (1) CN1207297C (hu)
AP (1) AP1400A (hu)
AR (1) AR032628A1 (hu)
AT (1) ATE286901T1 (hu)
AU (2) AU2001272690B2 (hu)
BG (1) BG107266A (hu)
BR (1) BR0112734A (hu)
CA (1) CA2417264C (hu)
CZ (1) CZ2003126A3 (hu)
DE (1) DE60108398T2 (hu)
DO (1) DOP2001000217A (hu)
DZ (1) DZ3364A1 (hu)
EA (1) EA004681B1 (hu)
EC (1) ECSP034454A (hu)
EE (1) EE200300045A (hu)
ES (1) ES2231521T3 (hu)
GE (1) GEP20053494B (hu)
HK (1) HK1055954A1 (hu)
HR (1) HRP20030061A2 (hu)
HU (1) HUP0302982A3 (hu)
IL (1) IL153226A0 (hu)
IN (1) IN2002MU01649A (hu)
IS (1) IS6626A (hu)
MA (1) MA26931A1 (hu)
MX (1) MX233602B (hu)
MY (1) MY117831A (hu)
NO (1) NO324220B1 (hu)
NZ (1) NZ523226A (hu)
OA (1) OA12337A (hu)
PA (1) PA8523501A1 (hu)
PE (1) PE20020277A1 (hu)
PH (1) PH12001001922B1 (hu)
PL (1) PL365133A1 (hu)
PT (1) PT1305314E (hu)
SK (1) SK572003A3 (hu)
SV (1) SV2001000570A (hu)
TN (1) TNSN01112A1 (hu)
TW (1) TWI285643B (hu)
UA (1) UA72631C2 (hu)
UY (1) UY26854A1 (hu)
WO (1) WO2002010171A1 (hu)
YU (1) YU4703A (hu)
ZA (1) ZA200301457B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
KR100939890B1 (ko) 2005-05-12 2010-01-29 화이자 인코포레이티드 N-[1-(2-에톡시에틸)-5-(N-에틸-N-메틸아미노)-7-(4-메틸피리딘-2-일-아미노)-1H-피라졸로[4,3-d]피리미딘-3-카르보닐]메탄술폰아미드의 무수 결정 형태

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134442C (zh) * 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AP2001002234A0 (en) 2001-09-30
MA26931A1 (fr) 2004-12-20
BR0112734A (pt) 2004-08-10
DE60108398D1 (de) 2005-02-17
KR20030016430A (ko) 2003-02-26
PA8523501A1 (es) 2002-10-24
BG107266A (bg) 2003-07-31
AP1400A (en) 2005-04-28
IL153226A0 (en) 2003-07-06
CN1207297C (zh) 2005-06-22
EP1305314A1 (en) 2003-05-02
SK572003A3 (en) 2004-05-04
EA200300079A1 (ru) 2003-06-26
MXPA03000856A (es) 2003-06-06
CA2417264C (en) 2007-06-12
EP1305314B1 (en) 2005-01-12
SV2001000570A (es) 2002-09-03
MY117831A (en) 2004-08-30
HUP0302982A3 (en) 2005-01-28
MX233602B (es) 2006-01-10
NO20030416L (no) 2003-02-05
JP2004505087A (ja) 2004-02-19
UA72631C2 (uk) 2005-03-15
CA2417264A1 (en) 2002-02-07
HRP20030061A2 (en) 2003-04-30
CZ2003126A3 (cs) 2004-02-18
AU7269001A (en) 2002-02-13
NO20030416D0 (no) 2003-01-27
ATE286901T1 (de) 2005-01-15
AR032628A1 (es) 2003-11-19
PT1305314E (pt) 2005-04-29
PE20020277A1 (es) 2002-05-11
DZ3364A1 (fr) 2002-02-07
OA12337A (en) 2006-05-15
AU2001272690B2 (en) 2005-12-08
ZA200301457B (en) 2004-04-28
NO324220B1 (no) 2007-09-10
PL365133A1 (en) 2004-12-27
IS6626A (is) 2002-11-18
ES2231521T3 (es) 2005-05-16
UY26854A1 (es) 2002-02-28
EA004681B1 (ru) 2004-06-24
TWI285643B (en) 2007-08-21
KR100457937B1 (ko) 2004-11-20
CN1444585A (zh) 2003-09-24
TNSN01112A1 (fr) 2005-11-10
DE60108398T2 (de) 2005-12-22
GEP20053494B (en) 2005-04-25
IN2002MU01649A (hu) 2004-12-11
NZ523226A (en) 2003-07-25
DOP2001000217A (es) 2002-10-30
PH12001001922B1 (en) 2006-11-21
HK1055954A1 (en) 2004-01-30
ECSP034454A (es) 2003-03-10
EE200300045A (et) 2004-12-15
WO2002010171A1 (en) 2002-02-07
YU4703A (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
SE9704544D0 (sv) Novel compounds
SE9904505D0 (sv) Novel compounds
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
MXPA03010761A (es) Combinaciones farmaceuticas.
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
HUP0302982A2 (hu) Kristályos gyógyszer
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
MXPA04005809A (es) Inhibidores de proteinas quinasas.
HRP20050603A2 (en) Novel anticonvulsant derivative salts
IT1317049B1 (it) Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
EP1434762A4 (en) 4'-METHANSULFONYLBIPHENYL DERIVATIVES AS HIGH-DETECTIVE CYCLOOXYGENASE-2 INHIBITORS
WO2002024146A3 (en) Methods of decreasing or preventing pain using spicamycin derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees